Statement by ACRO Executive Director Doug Peddicord On House Passage of 21st Century Cures Act

July 10, 2015 (Washington, DC) – The Association of Clinical Research Organizations (ACRO) is pleased to see the passage of the 21st Century Cures Act, which will assist in the modernization of clinical trials that help bring new treatments to patients in need. We are especially encouraged that the legislation calls for enhancements to clinicaltrials.gov that will make the site more useful for patients and their physicians, streamlined institutional review board processes, promotion of data sharing and incorporation of real-world data into the research process, greater focus on patient-centered drug development, and increased funding for the Food and Drug Administration. Chairman Fred Upton (R-MI) and Representative Diana DeGette (D-CO) should be commended for their tireless efforts to pass this important legislation. ACRO looks forward to working with the Senate to advance these solutions into law.

About ACRO The Association of Clinical Research Organizations (ACRO) represents companies that provide a variety of specialized services that support the development of new pharmaceuticals, biologics, and medical devices. The Association provides an active voice for the CRO industry globally. Through its member companies, ACRO helps improve the quality, efficiency and safety of biomedical research. ACRO member companies employ more than 110,000 professionals worldwide, conduct research in 142 countries and contribute to the development of approximately 95% percent of all new drugs and biologics approved globally. For more information, please visit www.acrohealth.org. Twitter @acrohealth. YouTube @ACROHealthChannel. Facebook.RebelMouse.

Scroll to Top